Heart failure & cardiomyopathies
Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: A Multicentre Network Study
Authors' conclusion
Half of contemporary ATTRwt-CA diagnoses occur in a HF setting. These patients had worse clinical profile and outcome than those diagnosed either due to suspected HCM or incidentally, although prognosis remained primarily related to age, NYHA functional class and comorbidities rather than the diagnostic pathway itself.
Study context
- Population
- Patients diagnosed with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) at Italian referral centres
- Participants
- 1,281 patients
- Exposure
- Diagnostic pathways to ATTRwt-CA diagnosis
- Outcome
- Diagnostic pathway leading to ATTRwt-CA diagnosis; prognosis by all-cause mortality
Methodological detailsmulticentre, 17 Italian referral centres
- Multicentre
- 17 Italian referral centres
Main finding
As reported in the abstract
Diagnostic pathway
Observational data: associations, not effects.
Further findings
Patient characteristics, HF vs other pathways
- HF pathway patients older, with greater prevalence of New York Heart Association (NYHA) class III-IV and CKD
All-cause mortality
- Survival significantly worse in HF vs other pathways; similar among the three others
- Multivariate: older age, NYHA class III-IV and some comorbidities, but not HF pathway, independently associated with worse survival
Original publication
Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: A Multicentre Network Study. Eur J Heart Fail. Published 15 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →